FDA proposes cell and gene therapy site tours to help regulators learn from industry

In a federal register post Monday, the Office of Therapeutic Products (OTP) of the FDA’s Center for Biologics Evaluation and Research (CBER) unveiled its Cellular and Gene Therapies Interactive Site Tours Program. The initiative is designed to let CBER project managers and reviewers swap regulatory know-how with their industry counterparts on-site.